As another antibiotics biotech sinks into a crisis, warnings of a sector ‘collapse’
Another antibiotics company is scrambling to survive today, forcing the company’s founding CEO to exit in a reorganization that eliminates its research capabilities as the survivors look to improve on minuscule sales of their newly approved treatment. And the news — on top of an alarming series of failures — spurred at least one figure in the field to warn of a looming collapse of the antimicrobial resistance research field.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,500+ biopharma pros reading Endpoints daily — and it's free.